RxDoctor Payments Data

Tami Linscott

Family · Marietta, OHNPI 1255875548

Payments from drug & device makers

$722in general payments, 2019–2025

Across 32 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$212
  • AbbVie$177
  • Amgen$54
  • Novo Nordisk$49
  • Lilly USA, LLC$44
  • Pfizer$35
  • plus $150 from 8 others

What the payments were for

  • Food & beverage$722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$722 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$56,560
Medicare patients
235
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$114,502
EliquisApixaban59$58,992
JardianceEmpagliflozin39$52,518
FarxigaDapagliflozin Propanediol27$36,179
XareltoRivaroxaban32$32,335
TrulicityDulaglutide22$32,202
LinzessLinaclotide23$18,284
JanuviaSitagliptin Phosphate13$14,711
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,908
Tresiba Flextouch U-100Insulin Degludec11$10,525
Breo ElliptaFluticasone/Vilanterol19$9,808
Albuterol Sulfate HfaAlbuterol Sulfate232$8,429
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,248
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$7,097
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$114,50264 claims
PfizerEliquis$35$58,99259 claims
AstraZenecaFarxiga$14$36,17927 claims
Lilly USA, LLCTrulicity$44$32,20222 claims
GSKBreo Ellipta, Shingrix, Anoro Ellipta$32$24,11165 claims
AbbVieLinzess$177$18,28423 claims
MerckJanuvia$15$14,71113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →